Company: SCLXW
Filing Date: 2025-05-14
Form Type: 424B3
Source: 0001193125-25-119846
Chunk: 251

Company: Scilex Holding Co
Filing Date: 2025-05-14
Form: 424B3
Chunk 251
---
20 without receiving a repeat injection. |

| (2) | Quartiles are estimated using Kaplan-Meier estimation. |

| (3) | A Cox proportional hazards model was utilized to test the treatment difference while adjusting for site and 
 Pain Catastrophizing Scale (<30 or ≥30).                                                                    |

CI: confidence interval; ITT: intent-to-treat(randomized population); SD: standard deviation 165

Responder Analysis (Change from Baseline in Mean NPRS, Average Daily Pain in Affected Leg) (1)– ITT Population

|                                         |     | SP-102            
 N=202             |     | Placebo    
 N=199      |
| 30% reduction                           |     | 88 (43.6%)        |     | 57 (28.6%) |
| Chi-Square                              |     | P=0.002           |     |            |
| Logistic regression(2) (odds ratio [95% 
 CI])                                    |     | 1.96 (1.28, 2.98) |     |            |
|                                         |     | P=0.002           |     |            |
| 50% reduction                           |     | 58 (28.7%)        |     | 41 (20.6%) |
| Chi-Square                              |     | P=0.060           |     |            |
| Logistic regression(2) (odds ratio [95% 
 CI])                                    |     | 1.58 (0.99, 2.52) |     |            |
|                                         |     | P=0.055           |     |            |

| (1) | Patients that discontinued or have missing scores at Week Four were considered 
 non-responders.                                                                |

| (2) | Logistic regression models with treatment (SP-102 or placebo), site,                                                                                         
 and Pain Catastrophizing Scale group (<30 or ≥30), and baseline averaged daily pain score as factors were used to compare the treatment groups at each week. |

CI: confidence interval; ITT: intent-to-treat(randomized population) Phase 2 Repeat Dose Study- SP-102-03 We conducted an open-label, single-arm,pharmacodynamics (“PD”) and tolerability study of repeat epidural injections of SP-102in patients with sciatica. We conducted this study to characterize repeat dose PD with respect to hypothalamic-pituitary-adrenal suppression using plasma cortisol levels, white